Arcturus Therapeutics Holdings Stock Today
| ARCT Stock | USD 27.64 2.49 8.26% |
Performance0 of 100
| Odds Of DistressLess than 13
|
Arcturus Therapeutics is selling for under 27.64 as of the 18th of April 2024; that is -8.26 percent down since the beginning of the trading day. The stock's last reported lowest price was 27.47. Arcturus Therapeutics has less than a 13 % chance of experiencing some financial distress in the next two years of operation, but has generated negative returns over the last 90 days. Equity ratings for Arcturus Therapeutics Holdings are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 26th of October 2022 and ending today, the 18th of April 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of April 2020 | Category Healthcare | Classification Health Care |
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company was founded in 2013 and is headquartered in San Diego, California. The company has 26.92 M outstanding shares of which 4.81 M shares are presently shorted by private and institutional investors with about 8.56 trading days to cover. More on Arcturus Therapeutics Holdings
Moving against Arcturus Stock
| 0.64 | MRKR | Marker Therapeutics | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Financial Report 14th of May 2024
Arcturus Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Arcturus Therapeutics' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Arcturus Therapeutics or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | David Baker | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Arcturus Therapeutics report their recommendations after researching Arcturus Therapeutics' financial statements, talking to executives and customers, or listening in on Arcturus Therapeutics' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Arcturus Therapeutics. The Arcturus consensus assessment is calculated by taking the average forecast from all of the analysts covering Arcturus Therapeutics. | ||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Arcturus Therapeutics' liquidity, profitability, solvency, and operating efficiency, Arcturus Therapeutics Holdings is not in a good financial situation at this time. It has a very high odds of going through financial crisis in May. Financial strength of Arcturus Therapeutics is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||
Arcturus Therapeutics' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Arcturus Therapeutics' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Arcturus Therapeutics' financial leverage. It provides some insight into what part of Arcturus Therapeutics' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
Arcturus Therapeutics Holdings (ARCT) is traded on NASDAQ Exchange in USA. It is located in 10628 Science Center Drive, San Diego, CA, United States, 92121 and employs 180 people. Arcturus Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 743.94 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Arcturus Therapeutics's market, we take the total number of its shares issued and multiply it by Arcturus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Arcturus Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 26.92 M outstanding shares of which 4.81 M shares are presently shorted by private and institutional investors with about 8.56 trading days to cover.
Arcturus Therapeutics Holdings currently holds about 283.49 M in cash with (18.1 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.67.
Check Arcturus Therapeutics Probability Of Bankruptcy
Ownership AllocationArcturus Therapeutics holds a total of 26.92 Million outstanding shares. The majority of Arcturus Therapeutics Holdings outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Arcturus Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Arcturus Therapeutics. Please pay attention to any change in the institutional holdings of Arcturus Therapeutics Holdings as this could imply that something significant has changed or is about to change at the company. Also note that nearly two hundred sixty-nine thousand one hundred fifty-two invesors are currently shorting Arcturus Therapeutics expressing very little confidence in its future performance.
Check Arcturus Ownership Details
Arcturus Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Arcturus Therapeutics jumping above the current price in 90 days from now is about 99.0%. The Arcturus Therapeutics Holdings probability density function shows the probability of Arcturus Therapeutics stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 2.4405. This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Arcturus Therapeutics will likely underperform. Additionally, arcturus Therapeutics Holdings has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Arcturus Therapeutics to move above the current price in 90 days from now is about 99.0 (This Arcturus Therapeutics Holdings probability density function shows the probability of Arcturus Stock to fall within a particular range of prices over 90 days) .
Arcturus Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Arcturus Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Arcturus Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Arcturus Therapeutics' value.| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2023-12-31 | 582 K | |
| Geode Capital Management, Llc | 2023-12-31 | 538.3 K | |
| Granahan Investment Management Inc.. | 2023-12-31 | 450.4 K | |
| Jupiter Asset Management Limited | 2023-12-31 | 362.3 K | |
| Point72 Asset Management, L.p. | 2023-09-30 | 335.3 K | |
| Jpmorgan Chase & Co | 2023-12-31 | 322.8 K | |
| Northern Trust Corp | 2023-12-31 | 247 K | |
| Wayne Hummer Asset Mgmt Company | 2023-12-31 | 207.1 K | |
| Nuveen Asset Management, Llc | 2023-12-31 | 194.7 K | |
| Federated Hermes Inc | 2023-12-31 | 4.7 M | |
| Blackrock Inc | 2023-12-31 | 2.4 M |
Arcturus Therapeutics Historical Income Statement
Arcturus Therapeutics Holdings Income Statement is one of the three primary financial statements used for reporting Arcturus's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Arcturus Therapeutics revenue and expense. Arcturus Therapeutics Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Arcturus Therapeutics' Net Income From Continuing Ops is comparatively stable compared to the past year. Net Income Applicable To Common Shares is likely to gain to about 8.8 M in 2024, whereas EBIT is likely to drop (4.4 M) in 2024. View More FundamentalsArcturus Stock Against Markets
Picking the right benchmark for Arcturus Therapeutics stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Arcturus Therapeutics stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Arcturus Therapeutics is critical whether you are bullish or bearish towards Arcturus Therapeutics Holdings at a given time. Please also check how Arcturus Therapeutics' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Arcturus Therapeutics without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Idea Optimizer Now
Idea OptimizerUse advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
| All Next | Launch Module |
Arcturus Therapeutics Corporate Directors
Arcturus Therapeutics corporate directors refer to members of an Arcturus Therapeutics board of directors. The board of directors generally takes responsibility for the Arcturus Therapeutics' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Arcturus Therapeutics' board members must vote for the resolution. The Arcturus Therapeutics board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| David Shapiro | Director | Profile | |
| Peter Farrell | Director | Profile | |
| James Barlow | Director | Profile | |
| Magda Marquet | Director | Profile |
How to buy Arcturus Stock?
Before investing in Arcturus Therapeutics, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Arcturus Therapeutics. To buy Arcturus Therapeutics stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Arcturus Therapeutics. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Arcturus Therapeutics stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Arcturus Therapeutics Holdings stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Arcturus Therapeutics Holdings stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Arcturus Therapeutics Holdings, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Arcturus Stock please use our How to Invest in Arcturus Therapeutics guide.
Already Invested in Arcturus Therapeutics Holdings?
The danger of trading Arcturus Therapeutics Holdings is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Arcturus Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Arcturus Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Arcturus Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Arcturus Therapeutics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Arcturus Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Arcturus Therapeutics Holdings Stock. Highlighted below are key reports to facilitate an investment decision about Arcturus Therapeutics Holdings Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Arcturus Therapeutics Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Arcturus Therapeutics information on this page should be used as a complementary analysis to other Arcturus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Arcturus Stock analysis
When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |
Is Arcturus Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcturus Therapeutics. If investors know Arcturus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcturus Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.12) | Revenue Per Share 6.264 | Quarterly Revenue Growth (0.81) | Return On Assets (0.11) | Return On Equity (0.11) |
The market value of Arcturus Therapeutics is measured differently than its book value, which is the value of Arcturus that is recorded on the company's balance sheet. Investors also form their own opinion of Arcturus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Arcturus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcturus Therapeutics' market value can be influenced by many factors that don't directly affect Arcturus Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcturus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcturus Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcturus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.